View Exam | PowerPak

1. The number of new cases of acute myeloid leukemia is highest in which age group?

A. 50 to 54 years old B. 60 to 64 years old C. 70 to 74 years old D. 80 to 84 years old E. Unsure

2. Which patient groups experienced improved overall survival in the follow-up phase of the pivotal trial that led to the approval of midostaurin?

A. All FMS-like tyrosine kinase 3 (FLT3) mutation-positive subgroups benefitted B. Only patients with internal tandem duplication (ITD) mutations benefited C. Only patients with tyrosine kinase domain (TKD) mutations benefited D. Only patients with ITD and TKD mutations benefited E. Unsure

3. What is an appropriate midostaurin dosage in an induction regimen that includes daunorubicin and cytarabine in a patient with FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia?

A. 100 mg orally twice daily on days 8 to 21 of each induction cycle with daunorubicin and cytarabine B. 100 mg orally once daily on days 8 to 21 of each induction cycle with daunorubicin and cytarabine C. 50 mg orally twice daily on days 8 to 21 of each induction cycle with daunorubicin and cytarabine D. 50 mg orally once daily on days 8 to 21 of each induction cycle with daunorubicin and cytarabine E. Unsure

4. What is an appropriate antiemetic regimen prior to initiating midostaurin in a consolidation regimen that includes high-dose cytarabine in a patient with FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia?

A. Dexamethasone on day 1 B. Dexamethasone and a 5-HT3 receptor antagonist C. Dexamethasone, a 5-HT3 receptor antagonist, and an NK-1 antagonist D. Dexamethasone and a 5-HT3 receptor antagonist, with an option to include an NK-1 antagonist in patients with additional risk factors prior to cytarabine dosing E. Unsure

5. A patient with acute myeloid leukemia is receiving consolidation therapy with midostaurin. In which of the following cases should midostaurin be discontinued?

A. The patient shows signs and symptoms of interstitial lung disease B. The patient has confirmed bacterial pneumonia C. The patient has been diagnosed with an upper respiratory tract infection D. The patient has developed a wet cough E. Unsure

6. The pivotal trials that led to the approval of enasidenib included patients with what type of acute myeloid leukemia (AML)?

A. Newly diagnosed AML B. AML secondary to prior chemotherapy C. Relapsed or refractory AML D. AML associated with genetic disorders E. Unsure

7. Which adverse event is not associated with isocitrate dehydrogenase 2 (IDH2) inhibition in patients with acute myeloid leukemia being treated with enasidenib?

A. Differentiation syndrome B. Leukocytosis C. Tumor lysis syndrome D. Veno-occlusive disease E. Unsure

8. Changes in which lab parameter may be an early indication of tumor lysis syndrome in a patient with acute myeloid leukemia being treated with enasidenib?

A. Bilirubin B. Lactic dehydrogenase C. Potassium D. Urea E. Unsure

9. Which of the following adverse events was more common in patients with acute myeloid leukemia treated with a standard 7+3 regimen than in those treated with liposomal daunorubicin and cytarabine?

A. There were no differences in adverse events B. Edema C. Febrile neutropenia D. Rash E. Unsure

10. What is the appropriate action in a patient with acute myeloid leukemia that has a documented cardiac arrythmia and is considering induction therapy with liposomal daunorubicin and cytarabine?

A. Assess cardiac risk factors and ejection fraction prior to initiating therapy B. Initiate liposomal daunorubicin and cytarabine; perform monthly cardiac assessment C. Initiate liposomal daunorubicin and cytarabine; perform bi-monthly cardiac assessment D. Initiate liposomal daunorubicin and cytarabine; perform weekly cardiac assessment E. Unsure

11. What should be done to manage leukocytosis in a patient with acute myeloid leukemia being treated with enasidenib?

A. Administer allopurinol B. Initiate hydroxyurea C. Reduce enasidenib dose D. Discontinue enasidenib E. Unsure

12. In a patient with acute myeloid leukemia being treated with gemtuzumab ozogamicin, which symptom does NOT warrant assessment for veno-occlusive disease?

A. Ascites B. Elevated bilirubin C. Fever D. Weight gain E. Unsure

Evaluation Questions

13. How confident are you in your recommendation on the management of leukocytosis for the above patient?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

14. How confident are you in your treatment of symptoms for the above patient?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The number of new cases of acute myeloid leukemia is highest in which age group?

2. Which patient groups experienced improved overall survival in the follow-up phase of the pivotal trial that led to the approval of midostaurin?

3. What is an appropriate midostaurin dosage in an induction regimen that includes daunorubicin and cytarabine in a patient with FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia?

4. What is an appropriate antiemetic regimen prior to initiating midostaurin in a consolidation regimen that includes high-dose cytarabine in a patient with FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia?

5. A patient with acute myeloid leukemia is receiving consolidation therapy with midostaurin. In which of the following cases should midostaurin be discontinued?

6. The pivotal trials that led to the approval of enasidenib included patients with what type of acute myeloid leukemia (AML)?

7. Which adverse event is not associated with isocitrate dehydrogenase 2 (IDH2) inhibition in patients with acute myeloid leukemia being treated with enasidenib?

8. Changes in which lab parameter may be an early indication of tumor lysis syndrome in a patient with acute myeloid leukemia being treated with enasidenib?

9. Which of the following adverse events was more common in patients with acute myeloid leukemia treated with a standard 7+3 regimen than in those treated with liposomal daunorubicin and cytarabine?

10. What is the appropriate action in a patient with acute myeloid leukemia that has a documented cardiac arrythmia and is considering induction therapy with liposomal daunorubicin and cytarabine?

11. What should be done to manage leukocytosis in a patient with acute myeloid leukemia being treated with enasidenib?

12. In a patient with acute myeloid leukemia being treated with gemtuzumab ozogamicin, which symptom does NOT warrant assessment for veno-occlusive disease?

Evaluation Questions

13. How confident are you in your recommendation on the management of leukocytosis for the above patient?

14. How confident are you in your treatment of symptoms for the above patient?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The number of new cases of acute myeloid leukemia is highest in which age group?

2. Which patient groups experienced improved overall survival in the follow-up phase of the pivotal trial that led to the approval of midostaurin?

3. What is an appropriate midostaurin dosage in an induction regimen that includes daunorubicin and cytarabine in a patient with FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia?

4. What is an appropriate antiemetic regimen prior to initiating midostaurin in a consolidation regimen that includes high-dose cytarabine in a patient with FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia?

5. A patient with acute myeloid leukemia is receiving consolidation therapy with midostaurin. In which of the following cases should midostaurin be discontinued?

6. The pivotal trials that led to the approval of enasidenib included patients with what type of acute myeloid leukemia (AML)?

7. Which adverse event is not associated with isocitrate dehydrogenase 2 (IDH2) inhibition in patients with acute myeloid leukemia being treated with enasidenib?

8. Changes in which lab parameter may be an early indication of tumor lysis syndrome in a patient with acute myeloid leukemia being treated with enasidenib?

9. Which of the following adverse events was more common in patients with acute myeloid leukemia treated with a standard 7+3 regimen than in those treated with liposomal daunorubicin and cytarabine?

10. What is the appropriate action in a patient with acute myeloid leukemia that has a documented cardiac arrythmia and is considering induction therapy with liposomal daunorubicin and cytarabine?

11. What should be done to manage leukocytosis in a patient with acute myeloid leukemia being treated with enasidenib?

12. In a patient with acute myeloid leukemia being treated with gemtuzumab ozogamicin, which symptom does NOT warrant assessment for veno-occlusive disease?

Evaluation Questions

13. How confident are you in your recommendation on the management of leukocytosis for the above patient?

14. How confident are you in your treatment of symptoms for the above patient?

« Return to Activity

Customers who Purchased
this Activity also Purchased